Lauflumide (NLS-4) Is a New Potent Wake-Promoting Compound

Area of Science:

• Neuroscience
• Pharmacology
• Sleep Medicine

Background:

• Psychostimulants are crucial for treating excessive daytime sleepiness in various sleep disorders and cognitive impairments.
• Understanding novel wake-promoting agents is essential for developing effective treatments.

Purpose of the Study:

• To evaluate the wake-promoting effects of NLS-4 in mice.
• To compare NLS-4's impact on sleep architecture and EEG power densities with modafinil and vehicle.

Main Methods:

• C57BL/6J mice received intraperitoneal injections of vehicle, NLS-4 (64 mg/kg), or modafinil (150 mg/kg).
• Continuous EEG and EMG recordings were analyzed for 24 hours to assess vigilance states and EEG power densities.
• Spectral analysis focused on NREM EEG delta and theta frequency ranges.

Main Results:

• NLS-4 significantly increased wakefulness duration more than modafinil.
• While neither drug caused significant sleep rebound, modafinil-treated mice exhibited more NREM sleep than NLS-4 treated mice.
• NLS-4 altered NREM EEG spectral power, increasing delta activity and decreasing theta activity, unlike modafinil.

Conclusions:

• NLS-4 is a potent wake-promoting agent with no observed hypersomnia rebound.
• Recovery sleep following NLS-4 administration showed reduced NREM sleep and delta activity, indicating a potentially lower need for recovery despite extended wakefulness.